Alopecia areata: an update
Keywords:
Alopecia areata, etiology, pathogenesis, managementAbstract
Alopecia areata (AA) is a nonscarring, autoimmune hair loss on the scalp, and/or body. Etiology and pathogenesis are still unknown. The most common site affected is the scalp in the form of solitary or multiple patches of alopecia. Histopathology is characterized by an increased number of telogen follicles and presence of inflammatory lymphocytic infiltrate in the peribulbar region. Corticosteroids are the most popular drugs for the treatment of this disease. This review precisely outlines the etiologic and pathogenic mechanisms, clinical features, diagnosis and management of alopecia areata.ÂReferences
James WD, Berger TG, Elston DM. Andrews' Diseases of the Skin: Clinical Dermatology. 10th edn. Philadelphia: Saunders Elsevier; 2006.
Safavi KH, Muller SA, Suman VJ et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc. 1995;70:628-33.
Sharma VK, Dawn G, Kumar B. Profile of alopecia areata in Northern India. Int J Dermatol. 1996;35:22-7.
McDonagh AJ, Tazi-Ahnini R. Epidemiology and genetics of alopecia areata. Clin Exp Dermatol. 2002;27:405-9.
Hordinsky M, Ericson M. Autoimmunity: Alopecia areata. J Invest Dermatol Symp Proc. 2004;9:73-8.
Brenner R. Coincidences of alopecia areata, vitiligo, onychodystrophy, localized scleroderma and lichen planus. Dermatologica. 1979;159:356-8.
Ruiz-Doblado S, Carrizosa A, Garcia-Hernandez MJ. Alopecia areata: psychiatric comorbidity and adjustment to illness. Int J Dermatol. 2003;42:434-7.
Trueb RM. Systematic approach to hair loss in women. Indian Clin Updates-Dermatology 2010;2:284-97.
Paus R. Control of the hair cycle and hair diseases as cycling disorders. Curr Opin Dermatol. 1996;3:248-58.
Wasserman D, Guzman-Sanchez DA, Scott K, McMichael A. Alopecia areata. Int J Dermatol. 2007;46:121-31.
Tosti A, La Placa M, Placucci F et al. No correlation between cytomegalovirus and alopecia areata. J Invest Dermatol. 1996;107:443.
Yang S, Yang J, Liu JB et al. The genetic epidemiology of alopecia areata in China. Br J Dermatol. 2004;151:16-23.
McMichael AJ. The genetic epidemiol autoimmune pathogenesis alopecia areata. J Eur Acad Dermatol Venereol. 1997;9:36-43.
McDonagh AJ, Tazi-Ahnini R. Epidemiology and genetics of alopecia areata. Clin Exp Dermatol. 2002;27:405-9.
Kavak A, Baykal C, Ozarmagan G, Akar U. HLA in alopecia areata. Int J Dermatol. 2000;39:598-92.
Barahmani N, de Andrade M, Slusser JP et al. Major histocompatibility complex class I chain-related gene A polymorphisms and extended haplotypes are associated with familial alopecia areata. J Invest Dermatol. 2006;126:74-8.
Hordinsky M, Ericson M. Autoimmunity: Alopecia areata. J Investig Dermatol Symp Proc. 2004;9:73-8.;
Gilhar A, Kalish R. Alopecia areata: a tissue-specific autoimmune disease of the hair follicle. Autoimmunity Rev. 2006;5:64-9.
Tan E, Tay Y-K, Goh CL et al. The pattern of alopecia areata in Singapore – a study of 219 Asians. Int J Dermatol. 2002;41:748-53.
Tan E, Tay YK, Giam YC. A clinical study of childhood alopecia areata in Singapore. Pediatric Dermatol. 2002;19:298-301.
Camacho F. Alopecia areata. Clinical characteristics and dermatopathology, in Trichology: diseases of the pilosebaceous follicle 1997, Madrid, Aula Medical Group, S. A. 471–440.
Zoe Diana Draelos (August 30, 2007), Alopecia Areata. MedicineNet.com. Retrieved on May 11 , 2011.
Cline DJ. Changes in hair color. Dermatol Clin. 1988;6:295-303.
Finner AM. Alopecia areata: Clinical presentation, diagnosis, and unusual cases. Dermatol Ther. 2011;24:348-54.
Olsen EA. Hair. In: Freedberg IM, editors. Fitzpatrick’s Dermatology in General Medicine. New York: McGraw-Hill; 2003. P.641-3.
Olsen EA, Hordinsky MK, Price VH et al. National Alopecia Areata Foundation. Alopecia areata investigational assessment guidelines. part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51:440-7.
Price VH, Gummer CL. Loose anagen syndrome. J Am Acad Dermatol. 1989;20:249-56.
Lew B-L, Shin M-K, Sim W-Y. Acute diffuse and total alopecia: A new subtype of alopecia areata with a favorable prognosis. J Am Acad Dermatol. 2009;60:85-93.
Garcia-Hernandez MJ. CFM. Atypical clinical forms of alopecia areata. In: Camacho Francisco MR, Price Vera H, eds. Hair and its Disorders: Biology, Pathology, and Management. London: Martin Dunitz; 2000. P.228-31.
Ragunatha S, Inamadar AC, Palit A et al. Diffuse nonscarring alopecia of scalp: an indicator of early infantile scurvy? Pediatr Dermatol. 2008;25:644-6.
Whiting DA. Histopathologic features of alopecia areata: a new look. Arch Dermatol. 2003;139:1555-9.
Igarashi R, Moroashi M, Takeuchi S. Immunofluorescence studies on complement components in the hair follicles of normal scalp and of scalp affected by alopecia areata. Acta Derm Venreo.l 1981;61:131-5.
Shimmer BP, Parker KL, eds. Goodman’s and Gillman’s: The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2001. P.1661-3.
Ross EK, Shapiro J. Management of hair loss. Dermatol Clin. 2005;23:227-43.
Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol. 2000;42:549-66.
Pascher F, Kurtin S, Andrade R. Assay of 0.2 percent fluocinolone acetonide cream for alopecia areata and totalis. Efficacy, side effects including histologic study ensuing localized acneiform response. Dermatologica. 1970;141:193-202.
Tosti A, Piraccini BM, Pazzaglia M et al. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol. 2003;49:96-8.
Burton JL, Shuster S. Large doses of glucocorticoid in the treatment of alopecia areata. Acta Derm Venereol. 1975;55:493-6.
Friedli A, Labarthe MP, Engelhardt E et al. Pulse methylprednisolone therapy for severe alopecia areata: an open prospective study of 45 patients. J Am Acad Dermatol. 1998;39:597-602.
Pasricha JS, Kumrah L. Alopecia totalis treated with oral mini-pulse (OMP) therapy with betamethasone. Indian J Dermatol Venereol Leprol. 1996;62:106-9.
Dickerman RD, Jaikumar S. The hiccup reflex arc and persistent hiccups with high dose anabolic steroids: Is the brainstem the steroid-responsive locus? Clin Neuropharmacol. 2001;24:62-4.
Fiedler VC, Wendrow A, Szpunar GJ et al. Treatment resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin. Arch Dermatol. 1990;126:756-9.
Buhl AE. Minoxidil’s action in hair follicles. J Invest Dermatol. 1991;96:73S–74S.
Fransway AF, Muller SA. 3 Percent topical minoxidil compared with placebo for the treatment of chronic severe alopecia areata. Cutis. 1988;41:431-5.
Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol. 1987;16:730-6.
Ross EK, Shapiro J. Management of hair loss. Dermatol Clin. 2005;23:227-43.
Thappa DM, Vijayikumar M. Alopecia areata. Indian J Dermatol Venereol Leprol. 2001;67:187-90.
Rosenberg EW, Drake L. In: Discussion of Dunaway DA. Alopecia areata. Arch Dermatol. 1976;112:256.
Van der Steen PH, van Baar HM, Happle R et al. Prognostic factors in the treatment of alopecia areata with diphenylcyclopropenone. J Am Acad Dermatol. 1991;24:227-30.
Happle R, Echternacht K. Induction of hair growth in alopecia areata with DNCB. Lancet. 1977;2:1002-3.
Galbraith GMP, Thiers BH, Fundenberg HH. An open-label trial of immunomodulation therapy with Inosiplex (Isoprinosine) in patients with alopecia totalis and cell mediated immunodeficiency, J Am Acad Dermatol. 1984;11:224-30.
Whitmont K, Cooper A. PUVA treatment of alopecia areata totalis and universalis: a retrospective study. Australas J Dermatol. 2003;44:106-9.
Mohamed Z, Bhouri A, Jallouli A et al. Alopecia areata treatment with a phototoxic dose of UVA and topical 8- methoxypsoralen. J Eur Acad Dermatol Venereol. 2005;19:552-5.
Sharma PK, Jain RK, Sharma AK. PUVASOL therapy in alopecia areata. Indian J Dermatol Venereol Leprol. 1990;56:301-3
Taylor M, Ashcroft AT, Messenger AG. Cyclosporin A prolongs human hair growth in vitro. J Invest Dermatol. 1993;100:237-9.
Gupta AK, Ellis CN, Nickoloff BJ et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol. 1990;126:339-50.
Lawrence ID. Tacrolimus (FK506): experience in dermatology. Dermatol Ther. 1998;5:74-84.
Yamamoto S, Jiang H, Kato R. Stimulation of hair growth by topical application of FK506, a potent immunosuppressive agent. J Invest Dermatol. 1994;102:160-4.
Jiang H, Yamamoto S, Kato R. Induction of anagen in telogen mouse skin by topical application of FK506, a potent immunosuppressant. J Invest Dermatol 1995;104:523-5.
Ellis CN, Brown MF, Voorhees JJ. sulfasalazine for alopecia areata. J Am Acad Dermatol. 2002;46:541-4.
Rashidi T, Mahd AA. Treatment of persistent alopecia areata with sulfasalazine. Int J Dermatol. 2008;47:850-2.
Olsen AE. Female pattern hair loss. J Am Acad Dermatol. 2001;45:S70-80.
Strober B, Siu K, Alexis A et al. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. J Am Acad Dermatol. 2005;52:1082-4.
